***  For details on how to be removed from this list visit the  ***
***          CCP4 home page http://www.ccp4.ac.uk         ***


Protein Crystallographer - AstraZeneca,Mölndal

AstraZeneca is now looking for a PhD with hands on experience of protein
crystallography. This one year temporary position will be placed in the
crystallography group at the Structural Chemistry Laboratory at AstraZeneca
R&D Mölndal, Sweden.

The Structural Chemistry Laboratory, Mölndal is a centre of excellence
supporting the AstraZeneca discovery organizations in Sweden, UK and US. 
The laboratory has around 35 scientists engaged in experimental research and
the core disciplines are protein engineering, NMR spectroscopy and protein
crystallography. The lab is excellently equipped with state of the art
equipment. Recently a full set of robotics has been installed to support the
process from protein crystallization to data collection.

The successful candidate will join one of the sub-teams and work in direct
support of one of the therapeutic areas. This is an excellent opportunity
for a structural scientist to gain experience from the international and
multidisciplinary environment within one of the worlds leading
pharmaceutical companies.

The candidate will mainly be involved in the support of structure-based
drug-design projects. The candidate should therefore have a strong genuine
interest in and experience from studying molecular interactions by
crystallography preferentially in a pharmaceutical environment. Experience
from synchrotron and computational work and an organized working-practice
are strictly necessary requirements. A background in organic chemistry,
biochemistry or biophysics is advantageous.

The position requires enthusiasm, flexibility and a natural talent to
interact in a team as well as the ability to communicate effectively.

For additional information, please contact Helena Käck AstraZeneca, +46 708
467091, [EMAIL PROTECTED]

Please send your application and CV marked "71-11546 Protein
Crystallographer" no later than June 6, 2006 via www.astrazeneca.com We will
only consider applications received via our website.

Reply via email to